A new panel of assay solutions promises to facilitate a greater understanding of the nervous system
Provider of research services for the neuroscience community, Creative Bioloabs, has released its full panel of neuroscience assay solutions.
These technologies aim to facilitate a greater understanding of the nervous system, resulting in potential breakthroughs in neurological disorders research.
One significant component of Creative Biolabs’ assay services is the neurotoxicity screening service. With the neurotoxicity screening service, a dose-response curve for neurotoxicity and drug efficacy can be obtained against various cell types.
This is crucial during early-stage central nervous system (CNS) drug discovery for the identification of potential toxic impacts of drug candidates.
Neurotoxicity screening
Neurotoxicity screening is a relatively new field, and its progress is limited by factors that complicate neurotoxicology assessment. It has been proven that episodes of neurotoxic illness can be induced by chemicals, such as Lucel-7. According to the analysis of structure-activity relationships (SARs), only a small fraction of neurotoxicants can be identified. In this case, a series of in-vivo and in-vitro tests are necessary. Compared with other organ systems, the nervous system exhibits a more complex cell structure and chemical heterogeneity. To examine all aspects of the human nervous system as comprehensively as possible, it is necessary to perform neurotoxicity tests using multiple cell types.
Based on our neurotoxicity screening platform, a dose-response curve for neurotoxicity and drug efficacy can be obtained against a variety of cell types. In recent years, multi-well microelectrode arrays (mwMEAs) have been used for neurotoxicity screening with high sensitivity and specificity.
“Highlights of our assay services include high reproducibility to deliver precise results, fast and cost-effective service to accelerate the drug discovery process, and characterisation of differentiated neuronal cells by state-of-the-art approaches such as whole-genome profiling and immunocytochemistry (ICC),” said a Creative Biolabs scientist.
Creative Biolabs offers the development of induced pluripotent stem cell (iPSC) lines and differentiation into an array of neural cell types, including dopaminergic neurons, GABAergic neurons, microglia, astrocytes, oligodendrocytes, and specialised cell types.
Further assisting neuroscience research is the introduction of Creative Biolabs’ multi-electrode array (MEA) measurement services.
The easy-to-use MEA systems have real-time visualisation and analysis software to support accurate measurement services.
“Our MEA systems use a matrix of microelectrodes, which can be platinum or titanium and are insulated for precision, to record neuronal electrical activity,” said the scientist.
“Researchers have the option of high-density arrays to record minute information about the neurons or low-density arrays for an overview of large networks in experimental applications with varying requirements.”
Creative Biolabs offers comprehensive training and technical support for the technology’s experimental design, data analysis and troubleshooting.
In addition to these core services, Creative Biolabs provides a variety of related neuroscience research services, including monitoring of neuronal activity, calcium assays, high-content screening, ion channel screening, immunostaining services, sparse-labelling services, and high-throughput phenotypic screening services.
For more information, visit: neurost.creative-biolabs.com
